The rampant growth of the artificial intelligence-driven drug discovery industry and the creation of hundreds of new companies makes consolidation in the space inevitable and BenevolentAI Limited is looking at bolt-on opportunities.
So said the UK firm’s chair and acting CEO Francois Nader at the J.P. Morgan Healthcare Conference in San Francisco this week